Literature DB >> 26256859

Prostate cancer: AR splice variant dimerization-clinical implications.

Emmanuel S Antonarakis1, Jun Luo2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26256859     DOI： 10.1038/nrurol.2015.184

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  9 in total

1.  Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.

Authors:  Emmanuel S Antonarakis; Changxue Lu; Brandon Luber; Hao Wang; Yan Chen; Mary Nakazawa; Rosa Nadal; Channing J Paller; Samuel R Denmeade; Michael A Carducci; Mario A Eisenberger; Jun Luo
Journal:  JAMA Oncol       Date:  2015-08       Impact factor: 31.777

2.  AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.

Authors:  Emmanuel S Antonarakis; Changxue Lu; Hao Wang; Brandon Luber; Mary Nakazawa; Jeffrey C Roeser; Yan Chen; Tabrez A Mohammad; Yidong Chen; Helen L Fedor; Tamara L Lotan; Qizhi Zheng; Angelo M De Marzo; John T Isaacs; William B Isaacs; Rosa Nadal; Channing J Paller; Samuel R Denmeade; Michael A Carducci; Mario A Eisenberger; Jun Luo
Journal:  N Engl J Med       Date:  2014-09-03       Impact factor: 91.245

3.  Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line.

Authors:  Clifford G Tepper; David L Boucher; Philip E Ryan; Ai-Hong Ma; Liang Xia; Li-Fen Lee; Thomas G Pretlow; Hsing-Jien Kung
Journal:  Cancer Res       Date:  2002-11-15       Impact factor: 12.701

4.  Androgen Receptor Splice Variants Dimerize to Transactivate Target Genes.

Authors:  Duo Xu; Yang Zhan; Yanfeng Qi; Bo Cao; Shanshan Bai; Wei Xu; Sanjiv S Gambhir; Peng Lee; Oliver Sartor; Erik K Flemington; Haitao Zhang; Chang-Deng Hu; Yan Dong
Journal:  Cancer Res       Date:  2015-06-09       Impact factor: 12.701

5.  Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer.

Authors:  Irfan A Asangani; Vijaya L Dommeti; Xiaoju Wang; Rohit Malik; Marcin Cieslik; Rendong Yang; June Escara-Wilke; Kari Wilder-Romans; Sudheer Dhanireddy; Carl Engelke; Mathew K Iyer; Xiaojun Jing; Yi-Mi Wu; Xuhong Cao; Zhaohui S Qin; Shaomeng Wang; Felix Y Feng; Arul M Chinnaiyan
Journal:  Nature       Date:  2014-04-23       Impact factor: 49.962

6.  Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer.

Authors:  Puranik Purushottamachar; Abhijit M Godbole; Lalji K Gediya; Marlena S Martin; Tadas S Vasaitis; Andrew K Kwegyir-Afful; Senthilmurugan Ramalingam; Zeynep Ates-Alagoz; Vincent C O Njar
Journal:  J Med Chem       Date:  2013-06-07       Impact factor: 7.446

7.  An androgen receptor N-terminal domain antagonist for treating prostate cancer.

Authors:  Jae-Kyung Myung; Carmen A Banuelos; Javier Garcia Fernandez; Nasrin R Mawji; Jun Wang; Amy H Tien; Yu Chi Yang; Iran Tavakoli; Simon Haile; Kate Watt; Iain J McEwan; Stephen Plymate; Raymond J Andersen; Marianne D Sadar
Journal:  J Clin Invest       Date:  2013-06-03       Impact factor: 14.808

8.  Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy.

Authors:  Bo Cao; Yanfeng Qi; Guanyi Zhang; Duo Xu; Yang Zhan; Xavier Alvarez; Zhiyong Guo; Xueqi Fu; Stephen R Plymate; Oliver Sartor; Haitao Zhang; Yan Dong
Journal:  Oncotarget       Date:  2014-03-30

9.  lncRNA-dependent mechanisms of androgen-receptor-regulated gene activation programs.

Authors:  Liuqing Yang; Chunru Lin; Chunyu Jin; Joy C Yang; Bogdan Tanasa; Wenbo Li; Daria Merkurjev; Kenneth A Ohgi; Da Meng; Jie Zhang; Christopher P Evans; Michael G Rosenfeld
Journal:  Nature       Date:  2013-08-14       Impact factor: 49.962
  9 in total
  5 in total

Review 1.  Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting.

Authors:  E S Antonarakis; A J Armstrong; S M Dehm; J Luo
Journal:  Prostate Cancer Prostatic Dis       Date:  2016-05-17       Impact factor: 5.554

Review 2.  Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting.

Authors:  Jun Luo; Gerhardt Attard; Steven P Balk; Charlotte Bevan; Kerry Burnstein; Laura Cato; Artem Cherkasov; Johann S De Bono; Yan Dong; Allen C Gao; Martin Gleave; Hannelore Heemers; Mayuko Kanayama; Ralf Kittler; Joshua M Lang; Richard J Lee; Christopher J Logothetis; Robert Matusik; Stephen Plymate; Charles L Sawyers; Luke A Selth; Howard Soule; Wayne Tilley; Nancy L Weigel; Amina Zoubeidi; Scott M Dehm; Ganesh V Raj
Journal:  Eur Urol       Date:  2017-12-16       Impact factor: 20.096

Review 3.  Development of AR-V7 as a putative treatment selection marker for metastatic castration-resistant prostate cancer.

Authors:  Jun Luo
Journal:  Asian J Androl       Date:  2016 Jul-Aug       Impact factor: 3.285

4.  Prostate cancer androgen receptor splice variant 7 biomarker study - a multicentre randomised feasibility trial of biomarker-guided personalised treatment in patients with advanced prostate cancer (the VARIANT trial) study protocol.

Authors:  Emma Clark; Miranda Morton; Shriya Sharma; Holly Fisher; Denise Howel; Jenn Walker; Ruth Wood; Helen Hancock; Rebecca Maier; John Marshall; Amit Bahl; Simon Crabb; Suneil Jain; Ian Pedley; Rob Jones; John Staffurth; Rakesh Heer
Journal:  BMJ Open       Date:  2019-12-18       Impact factor: 2.692

5.  Development of a High-Throughput Screening Assay for Small-Molecule Inhibitors of Androgen Receptor Splice Variants.

Authors:  Amy E Monaghan; Alison Porter; Irene Hunter; Angus Morrison; Stuart P McElroy; Iain J McEwan
Journal:  Assay Drug Dev Technol       Date:  2022-03-23       Impact factor: 2.471
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.